Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis

Obstetrics and Gynecology

Volumn 92, Issue 3, 1998, Pages 472-479

  Garg, Pushkal P ^a   Kerlikowske, Karla ^a,b   Subak, Leslee ^a,b   Grady, Deborah ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INVASION; CANCER RISK; DRUG INDUCED DISEASE; EPITHELIUM CELL; HIGH RISK POPULATION; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; OVARY CARCINOMA; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SALPINGOOOPHORECTOMY;

CARCINOMA; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 0031658944     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(98)00139-2     Document Type: Review

References (65)

1. Cauley J.A., Seeley D.G., Ensrud K., Ettinger B., Black D., Cummings S.R. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 122:1995;9-16.
2. Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willett W.C., Rosner B., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 335:1996;453-461.
3. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med. 117:1992;1038-1041.
4. American Academy of Family Physicians. Age charts for periodic health examination. Kansas City, Missouri: American Academy of Family Physicians, 1994.
5. American College of Obstetricians and Gynecologists. Hormone replacement therapy. ACOG technical bulletin no. 166. Washington DC: American College of Obstetricians and Gynecologists, 1992.
6. Canadian guide to clinical preventive health care. 1994;620-631 Canadian Communications Group, Ottawa.
7. Guide to clinical preventive services. 2nd ed. 1996;829-844 Williams & Wilkins, Baltimore.
8. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., Petitti D. Hormone replacement therapy and endometrial cancer risk A meta-analysis . Obstet Gynecol. 85:1995;304-313.
9. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E., Stampfer M.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332:1995;1589-1593.
10. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med. 316:1987;650-655.
11. Parazzini F., Franceschi S., La Vecchia C., Fasoli M. The epidemiology of ovarian cancer. Gynecol Oncol. 43:1991;9-23.
12. Thomas D.B. Estrogen replacement therapy and cancer Endometrial, breast, and ovarian . Korenman S.G. The menopause. 1990;101-118 Serono Symposia, Norwell, Massachusetts.
13. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1184-1203.
14. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1204-11.
15. Adami H.O., Persson I., Hoover R., Schairer C., Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer. 44:1989;833-839.
16. Annegers J.F., Strom H., Decker D.G., Dockerty M.B., O'Fallon W.M. Ovarian cancer Incidence and case-control study . Cancer. 43:1979;723-729.
17. Booth M., Beral V., Smith P. Risk factors for ovarian cancer A case-control study . Br J Cancer. 60:1989;592-598.
18. Cramer D.W., Hutchison G.B., Welch W.R., Scully R.E., Ryan K.J. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst. 71:1983;711-716.
19. Harlow B.L., Weiss N.S., Roth G.J., Chu J., Daling J.R. Case-control study of borderline ovarian tumors Reproductive history and exposure to exogenous female hormones . Cancer Res. 48:1988;5849-5852.
20. Hartge P., Hoover R., McGowan L., Lesher L., Norris H.J. Menopause and ovarian cancer. Am J Epidemiol. 127:1988;990-998.
21. Hempling R.E., Wong C., Piver M.S., Natarajan N., Mettlin C.J. Hormone replacement therapy as a risk factor for epithelial ovarian cancer Results of a case-control study . Obstet Gynecol. 89:1997;1012-1016.
22. Hildreth N.G., Kelsey J.L., LiVolsi V.A., Fischer D.B., Holford T.R., Mostow E.D., et al. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol. 114:1981;398-405.
23. Hoover R., Gray L.S., Fraumeni J.J. Stilboestrol (diethylstilbestrol) and the risk of ovarian cancer. Lancet. 2:1977;533-534.
24. Hunt K., Vessey M., McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy An updated analysis . Br J Obstet Gynaecol. 97:1990;1080-1086.
25. Kaufman D.W., Kelly J.P., Welch W.R., Rosenberg L., Stolley P.D., Warshauer M.E., et al. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol. 130:1989;1142-1151.
26. Parazzini F., La Vecchia C., Negri E., Villa A. Estrogen replacement therapy and ovarian cancer risk. Int J Cancer. 57:1994;135-136.
27. Persson I., Yuen J., Bergkvist L., Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - Long-term follow-up of a Swedish cohort. Int J Cancer. 67:1996;327-332.
28. Petitti D.B., Perlman J.A., Sidney S. Noncontraceptive estrogens and mortality Long-term follow-up of women in the Walnut Creek Study . Obstet Gynecol. 70:1987;289-293.
29. Polychronopoulou A., Tzonou A., Hsieh C.C., Kaprinis G., Rebelakos A., Toupadaki N., et al. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer. 55:1993;402-407.
30. Purdie D., Green A., Bain C., Siskind V., Ward B., Hacker N., et al. Reproductive and other factors and risk of epithelial ovarian cancer An Australian case-control study. Survey of Women's Health Study Group . Int J Cancer. 62:1995;678-684.
31. Risch H.A., Marrett L.D., Jain M., Howe G.R. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol. 144:1996;363-372.
32. Risch H.A. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol. 63:1996;254-257.
33. Rodriguez C., Calle E.E., Coates R.J., Miracle-McMahill H.L., Thun M.J., Heath C.W. Jr. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol. 141:1995;828-835.
34. Smith E.M., Sowers M.F., Burns T.L. Effects of smoking on the development of female reproductive cancers. J Natl Cancer Inst. 73:1984;371-376.
35. Tzonou A., Day N.E., Trichopoulos D., Walker A., Saliaraki M., Papapostolou M., et al. The epidemiology of ovarian cancer in Greece A case-control study . Eur J Cancer Clin Oncol. 20:1984;1045-1052.
36. Weiss N.S., Lyon J.L., Krishnamurthy S., Dietert S.E., Liff J.M., Daling J.R. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst. 68:1982;95-98.
37. Wu M.L., Whittemore A.S., Paffenbarger R.J., Sarles D.L., Kampert J.B., Grosser S., et al. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol. 128:1988;1216-1227.
38. Wynder E.L., Dodo H., Barber H.R. Epidemiology of cancer of the ovary. Cancer. 23:1969;352-370.
39. Casagrande J.T., Louie E.W., Pike M.C., Roy S., Ross R.K., Henderson B.E. "Incessant ovulation" and ovarian cancer. Lancet. 2:1979;170-173.
40. Nasca P.C., Greenwald P., Chorost S., Richart R., Caputo T. An epidemiologic case-control study of ovarian cancer and reproductive factors. Am J Epidemiol. 119:1984;705-713.
41. Whittemore A.S., Wu M.L., Paffenbarger R.S. Jr, Sarles D.L., Kampert J.B., Grosser S., et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol. 128:1988;1228-1240.
42. Byers T., Marshall J., Graham S., Mettlin C., Swanson M. A case-control study of dietary and nondietary factors in ovarian cancer. J Natl Cancer Inst. 71:1983;681-686.
43. McGowan L., Parent L., Lednar W., Norris H.J. The woman at risk for developing ovarian cancer. Gynecol Oncol. 7:1979;325-344.
44. Rosenberg L., Shapiro S., Slone D., Kaufman D.W., Helmrich S.P., Miettinen O.S., et al. Epithelial ovarian cancer and combination oral contraceptives. JAMA. 247:1982;3210-3212.
45. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 9:1987;1-30.
46. Miettinen O.S. Estimability and estimation in case-referent studies. Am J Epidemiol. 103:1976;226-235.
47. Dickersin K., Berlin J.A. Meta-analysis State-of-the-science . Epidemiol Rev. 14:1992;154-176.
48. Parazzini F., Restelli C., La Vecchia C., Negri E., Chiari S., Maggi R., et al. Risk factors for epithelial ovarian tumours of borderline malignancy. Int J Epidemiol. 20:1991;871-877.
49. Matthews K.A., Kuller L.H., Wing R.R., Meilahn E.N., Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 143:1996;971-978.
50. Shu X.O., Brinton L.A., Gao Y.T., Yuan J.M. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res. 49:1989;3670-3674.
51. Cannistra S.A. Cancer of the ovary. N Engl J Med. 329:1993;1550-1559.
52. Colditz G.A., Egan K.M., Stampfer M.J. Hormone replacement therapy and risk of breast cancer Results from epidemiologic studies . Am J Obstet Gynecol. 168:1993;1473-1480.
53. Sillero-Arenas M., Delgado-Rodriguez M., Rodigues-Canteras R., Bueno-Cavanillas A., Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer A meta-analysis . Obstet Gynecol. 79:1992;286-294.
54. Steinberg K.K., Thacker S.B., Smith S.J., Stroup D.F., Zack M.M., Flanders W.D., et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 265:1991;1985-1990.
55. Vierikko P., Kauppila A., Vihko R. Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in non-diseased tissue and in benign and malignant tumors of the human ovary. Int J Cancer. 32:1983;413-422.
56. Chien C.-H., Wang F.-F., Hamilton T.H. Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells. Mol Cell Endocrinol. 99:1994;11-19.
57. Helzlsouer K.J., Alberg A.J., Gordon G.B., Longcope C., Bush T.L., Hoffman S.C., et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA. 274:1995;1926-1930.
58. Gow S.M., Turner E.I., Glasier A. The clinical biochemistry of the menopause and hormone replacement therapy. Ann Clin Biochem. 31:1994;509-528.
59. Mercuri N., Petraglia F., Genazzani A.D., Amato F., Sgherzi M.R., Maietta-Latessa A., et al. Hormonal treatments modulate pulsatile plasma growth hormone, gonadotrophin and osteocalcin levels in postmenopausal women. Maturitas. 17:1993;51-62.
60. Larsson-Cohn U., Johansson E.D., Kagedal B., Wallentin L. Serum FSH, LH and oestrone levels in postmenopausal patients on oestrogen therapy. Br J Obstet Gynaecol. 85:1978;367-372.
61. Adashi E.Y. Clomiphene citrate Mechanism(s) and site(s) of action - A hypothesis revisited . Fertil Steril. 42:1984;331-344.
62. Rossing M.A., Daling J.R., Weiss N.S., Moore D.E., Self S.G. Ovarian tumors in a cohort of infertile women. N Engl J Med. 331:1994;771-776.
63. Markman M., Iseminger K.A., Hatch K.D., Creasman W.T., Barnes W., Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer A Gynecologic Oncology Group ancillary report . Gynecol Oncol. 62:1996;4-6.
64. Kosary CL, Ries LAG, Miller BA, Hankey BF, Harras A, Edwards BK. SEER cancer statistics review, 1973-1992: Tables and graphs. Bethesda, Maryland: National Cancer Institute, 1995. DHHS Publ No. (NIH)96-2789.
65. Sidney S., Petitti D.B., Quesenberry C.P. Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med. 127:1997;501-508.